Assessing screening methods for anal intraepithelial neoplasia in HPV patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the frequency of anal intraepithelial neoplasia (AIN) in patients who have survived HPV-related gynecological diseases. It will identify the risk of AIN associated with various HPV-related precancers and cancers. The study will utilize high-risk HPV testing and liquid cytology from both the lower genital tract and anal canal, followed by high-resolution anoscopy for potential biopsy and histopathological examination. The goal is to determine the most effective screening test for detecting AIN in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HPV related gynecological disease confirmed in histo-pathological examination
* the posibility to obtain material from gynecological organ and from anal canal

Where it's running

• PCK Marine Hospital in Gdynia
  Gdynia, Pomeranian Voivodeship, Poland Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 15-valent HPV vaccine for people aged 9–45 in China.

  This trial will test whether a 15‑valent HPV vaccine is safe and prompts immune responses in people aged 9–45.

  Recruiting Phase 2 Shanghai Bovax Biotechnology Co., Ltd. · Nanning, Guangxi · NCT06756269

• Risk of cervical cancer after HPV detection in healthy women

  This study tests how likely it is for cervical cancer to develop after different HPV detection patterns in healthy women who undergo HPV-based screening.

  Recruiting Karolinska Institutet · Stockholm · NCT07850128

• Dysplasix™ intravaginal suppositories for women with high‑risk HPV and mild cervical cell changes

  This trial tests whether nightly Dysplasix™ vaginal suppositories can clear high‑risk HPV and help mild cervical cell changes (ASC‑US or LSIL) in adult women.

  Recruiting Phase 2 Amplexd Therapeutics, Inc. · Shatin, New Territories · NCT07572396

• At-home HPV self-collection kits for cervical cancer screening

  We are testing different ways to give at-home HPV self-collection kits to under-screened people aged 25–65 to see if more of them complete cervical cancer screening and follow-up.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07453459

• Comparing clinic-only versus clinic plus community outreach to offer HPV self-collection for cervical screening in women with HIV

  This project will test whether adding community health worker outreach to clinic services helps more women living with HIV complete HPV self-collection for cervical screening.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Kampala · NCT07428330

• HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer

  This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07425054

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.